Overcoming acquired MET amplification after encorafenib-cetuximab in BRAF-V600E mutated colorectal cancer

被引：6
|
作者：
Ros, Javier [1 ]
Elez, Elena [1 ]
机构：
[1] Vall DHebron Hosp, Med Oncol, Barcelona, Spain
来源：
EUROPEAN JOURNAL OF CANCER | 2022年 / 172卷
关键词：
D O I：
10.1016/j.ejca.2022.06.026
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：326 / 328
页数：3
相关论文
共 50 条
  • [21] Safety of encorafenib, binimetinib, plus cetuximab for Japanese patients with BRAF V600E metastatic colorectal cancer
    Yamaguchi, Toshifumi
    Daisuke, Kotani
    Atsuo, Takashima
    Takeshi, Kato
    Toshiki, Masuishi
    Yoshito, Komatsu
    Manabu, Shiozawa
    Taito, Esaki
    Naoki, Izawa
    Shinji, Takeuchi
    Hideaki, Bando
    Satoru, Iwasa
    Hiroko, Hasegawa
    Taroh, Satoh
    Hiroya, Taniguchi
    Takayuki, Yoshino
    ANNALS OF ONCOLOGY, 2022, 33 : S479 - S479
  • [22] Effectiveness and safety of encorafenib-cetuximab in BRAFV600E metastatic colorectal cancer: Confidence study.
    Fernandez Montes, Ana
    Ros, Javier
    Grana, Begona
    Garcia-Alfonso, Pilar
    Brozos, Elena
    Melian, Marcos
    Jimenez-Gordo, Ana M.
    Martinez de Castro, Eva
    Busquier, Isabel
    Gallego, Javier
    Gravalos, Cristina
    Covela, Marta
    Ruiz-Casado, Ana
    Gonzalez Flores, Encarnacion
    Safont, Mariajose
    Maria Cano, Juana
    Alonso Lopez, Carmen
    Gomez-Reina, Maria Jose
    Donnay, Olga
    Aranda, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 126 - 126
  • [23] Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation
    Zaina T. Al-Salama
    Drugs, 2021, 81 : 849 - 856
  • [24] Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation
    Al-Salama, Zaina T.
    DRUGS, 2021, 81 (07) : 849 - 856
  • [25] Safety and efficacy of encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer: A systematic review and single-arm meta-analysis
    Celso, D. S. G.
    Defante, M. L. R.
    Alzogaray, V.
    Torres, L. A.
    Lopes, A. C. Melo
    Bearse, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S29 - S29
  • [26] A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study
    Martina Eriksen
    Per Pfeiffer
    Kristoffer Staal Rohrberg
    Christina Westmose Yde
    Lone Nørgård Petersen
    Laurids Østergaard Poulsen
    Camilla Qvortrup
    BMC Cancer, 22
  • [27] A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study
    Eriksen, Martina
    Pfeiffer, Per
    Rohrberg, Kristoffer Staal
    Yde, Christina Westmose
    Petersen, Lone Norgard
    Poulsen, Laurids Ostergaard
    Qvortrup, Camilla
    BMC CANCER, 2022, 22 (01)
  • [28] Efficacy and safety of the combination of encorafenib and cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: An AGEO real-world multicentre study
    Gallois, C.
    Elez Fernandez, M. E.
    Auclin, E.
    Bergen, E. S.
    Pernot, S.
    Higue, J.
    Trouilloud, I.
    Touchefeu, Y.
    Turpin, A.
    Mazard, T.
    Pilla, L.
    Cuissy, S.
    Wookey, V.
    Perret, A.
    Melchior, C.
    Artru, P.
    Stintzing, S.
    Dubreuil, O.
    Tougeron, D.
    Taieb, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S446 - S446
  • [29] BEACON CRC: safety lead-in (SLI) for the combination of binimetinib (BINI), encorafenib (ENCO), and cetuximab (CTX) in patients (pts) with BRAF-V600E metastatic colorectal cancer (mCRC)
    Huijberts, S.
    Schellens, J. H. M.
    Elez, E.
    Cuyle, P-J.
    Van Cutsem, E.
    Yaeger, R.
    Fakih, M.
    Montagut, C.
    Peeters, M.
    Desai, J.
    Yoshino, T.
    Ciardiello, F.
    Wasan, H.
    Grothey, A.
    Maharry, K.
    Gollerkeri, A.
    Kopetz, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [30] Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis
    Minoo, P.
    Moyer, M. P.
    Jass, J. R.
    JOURNAL OF PATHOLOGY, 2007, 212 (02): : 124 - 133
12345